By Kyle LaHucik – Endpoints News
Neurona Therapeutics has gathered $120 million in what is expected to be its last private financing round to wrap up an open-label study this year and move its epilepsy cell therapy into a randomized Phase II in 2025, CEO and co-founder Cory Nicholas told Endpoints News.
The financing brings the nine-year-old biotech’s total capital haul to date to about $285 million, Nicholas said, noting Neurona will assess market conditions about an initial public offering as its next financing step.
